Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Dostarlimab & Endometrial cancer (MMR-d/MSI-H), FDA granted accelerated approval in April 2021 and converted to full approval in February 2023 for adults with Endometrial cancer (MMR-d/MSI-H) that has progressed on or after platinum‑based therapy and is not amenable to curative surgery or radiation (1, 2)
EMA granted a conditional marketing authorization for dostarlimab monotherapy in adult patients with recurrent or advanced Endometrial cancer (MMR-d/MSI-H) that has progressed on or after platinum‑based chemotherapy, lat…